Astonishing numbers.
By age 17, about 1 in 1,000 privately insured minors were receiving gender-transition hormones between 2018 and 2022. This broke down to about 140 per 100,000 natal girls taking testosterone and 82 per 100,000 natal boys taking estrogen by this final year before teens hit the age of majority.
Compared with cross-sex hormones, puberty blockers were prescribed to adolescents with a transgender-related diagnosis at a much lower overall rate during this five-year period.
The youngest children to have received cross-sex hormones, the study authors found, were 12 years old, albeit at a vanishingly low rate. The rate of such prescriptions rose through the adolescents’ teen years and peaked at age 17, with use consistently higher among natal girls.
The rate of puberty blocker use peaked at age 13 for natal girls, at about 20 per 100,000 females at this age, and age 16 for natal boys, at about 18 per 100,000 such males.
https://benryan.substack.com/p/1-in-1000-privately-insured-17-year
And a link to the underlying source.
jamanetwork.com/journals/jamapediatrics/article-abstract/2828427?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamapediatrics.2024.6081